Ngm Biopharmaceuticals, Inc.

Daniel David Kaplan

Yan Wang

Hui Tian

Betty Chan Li

Kalyani Mondal

Jer-Yuan Hsu

Dana Yen Mei Duey

Suzanne Christine Crawley

Chia-Ying Kao Lam

Geoffrey William Stone

Zhaodan Cao

Yarong Lu

Julie Michelle Roda

Allen James Ebens, Jr

Xuecai Ge

Kevin James Paavola

Seth Malmersjö

Vicky Yi-Bing Lin

Peng Zhang

Jr Allen James Ebens

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

ILT-binding agents and methods of use thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

ILT3-binding agents and methods of use thereof

The present disclosure provides binding agents that modulate the interaction between liver-expressed antimicrobial peptide 2 (LEAP2) and growth hormone secretagogue receptor (GHSR). Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use to, e.g., treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes, increase growth hormone levels, or increase GHSR activity.

Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody

The present disclosure provides binding agents that modulate the interaction between LEAP2 and GHSR. Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use, to treat, ameliorate, or prevent a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes.

LEAP2 binding agents and compositions thereof

Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.

Methods of treating glucose metabolism disorders

Growing community of inventors

San Mateo, CA, United States of America

Daniel David Kaplan